Redeye comments on RLS Global´s Q3 2022 report. The report did not include any surprises, in our vie...
Redeye comments on Fluoguide’s Q3 2022 report at a time when the company is approaching multiple cri...
New Wave uppnår nya rekordnivåer för ett tredje kvartal i såväl omsättning som rörelseresultat.
Redeye comments on aXichem’s Q3 2022 report. The report did not include any surprises where sales ca...
Minor estimate revisions Balance sheet in better shape than we expected Currently trading at 7.
Redeye comments on CI Games Q3'22 report, which showed weaker profitability in the quarter.
Redeye comments on Enviro’s Q3 report, which held no surprises.
Redeye provides a first comment on the back of Northbaze Group’s Q3 report.
Redeye has a more positive view of Hexatronic’s US operations following a visit.
Redeye initiates coverage of Nepa, a scalable and rapidly growing software company in consumer scien...
Redeye updates valuation and estimates on Better Collective following its Q3-results which was sligh...
‘23e-‘24e EBITA estimates up 5% Working capital build-up sets high Q4 expectations Share trading at ...
Cutting costs by 10-20%: we lift ‘23e EBITDA by 20% Higher ASP and subscriptions to drive growth in ...
Q3 ARR ~2% lower vs. ABGSCe, adj. EBITDA better Reiterated guidance requires strong ARR growth in Q...
Imint’s revenue came in below our expectations, with margins inline.
Redeye leaves its comments on InDex Pharmaceuticals following its Q3 2022 report.
Rapportkommentar Omsättning för Q3 blev 17,5 mkr (8,9) upp 96% (71% CER).
Marknaden har förbisett Transtemas utveckling Vi initierar teckning på Transtema, marknadsledare i S...
Redeye is encouraged by the strong sales development, boosted by Catalyst contributing to c60% of US...
En hög efterfrågan, kortare ledtider och en stark leveransförmåga, i kombination med en god kostnads...
